信达生物(01801.HK)第三代肺癌靶向药物奥壹新获准上市

阿斯达克财经
27 Apr

信达生物(01801.HK) 公布,第三代表皮生长因子受体“EGFR”酪氨酸激酶抑制剂(“TKI”)靶向药物奥壹新(利厄替尼片)新药上市申请获中国国家药品监督管理局批准,用于具有EGFR外显子19缺失或外显子21置换突变的局部晚期或复发转移性非小细胞肺癌成人患者的一线治疗。

2024年10月,公司与江苏奥赛康就利厄替尼片在中国达成独家商业化合作。目前,奥壹新已在中国获批2项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10